Anuh Pharma Ltd (ANUHPHR) is currently trading at 97.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Anuh Pharma Limited is a leading manufacturer of Active Pharmaceutical Ingredients (APIs) and bulk drugs, prominently serving the antibiotics, erythromycin salts, and chloramphenicol market segments. Recently, Anuh Pharma has expanded its production capacity by commissioning an additional intermediate block, enhancing its capability to produce APIs and meet growing market demands. The company reported a 21.14% revenue growth in H1 FY 2025 compared to H1 FY 2024. However, a decline in EBITDA highlights challenges due to reduced high-margin product sales and non-recurring expenses. A continued focus on mature markets and dedicated R&D efforts in diabetic care and anti-malarial therapies further showcases Anuh Pharma's strategic initiatives to drive future growth. Anuh Pharma's commitment to clean energy and environmental responsibility is evident with new solar power installations and increased effluent treatment capacity to support sustainable operations.

Over the past 52 weeks, Anuh Pharma Ltd has traded between a low of ₹66.72 and a high of ₹99.50. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Anuh Pharma Ltd has a market capitalization of approximately 955.64. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Anuh Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 21.64 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 955.64 Cr, Anuh Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Anuh Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Anuh Pharma Ltd is 21.64. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Standalone revenue from operations was ₹193.81 crore and net profit after tax was ₹11.42 crore for the quarter ended 30 June 2026.

The board meeting is scheduled for May 20, 2026.

FY26 revenue from operations was ₹77,165.74 lakh and FY26 net profit was ₹4,104.61 lakh, as per the audited results disclosed.

The provided text states a board meeting is scheduled on 06/02/2026 to consider and approve unaudited financial results along with a limited review report.